Source:http://linkedlifedata.com/resource/pubmed/id/12021110
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2002-5-21
|
pubmed:abstractText |
This article aims to estimate the prevalence of SOX13 antibodies in Swedish patients with type 1 diabetes and healthy controls. The patients (n = 102; median age 35 years [range, 9-89]) were newly diagnosed with type 1 diabetes in a defined area in southern Sweden during 1995-1998. Islet cell antibodies (ICA) were analyzed with immunofluorescence, while glutamic acid decarboxylase antibodies (GADA), tyrosine phosphatase antibodies (IA-2A), and antibodies against the transcription factor SOX13 (SOX13Ab) were analyzed with radioimmunoprecipitating assays. SOX13Ab were found in 9.8% (10/102) of type 1 patients compared to 2.0% (2/99) in healthy controls (P = 0.033). At least one of the four autoantibodies (ICA, GADA, IA-2A or SOX13Ab) were identified in 67% (68/102) of the patients. Samples positive for IA-2A were only in one case positive also for SOX13Ab. IA-2A-positive patients were often positive also for ICA and GADA (19/27), and the same combination was also common for SOX13Ab-positive patients (6/10). Only 2.0% (2/102) were positive for SOX13Ab alone. ICA, GADA and IA-2A were more frequent in younger patients (<or= 35 years of age) than in older patients, while SOX13Ab showed similar frequency in both groups. We concluded that the frequency of SOX13Ab was significantly increased in Swedish patients with type 1 diabetes, but that the addition of SOX13Ab to the combination of GADA and IA2-A only increased the sensitivity by 2% for autoimmune diabetes. Therefore, SOX13 could be a minor autoantigen involved in the pathogenesis of type 1 diabetes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantigens,
http://linkedlifedata.com/resource/pubmed/chemical/High Mobility Group Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/SOX13 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/SOXD Transcription Factors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0077-8923
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
958
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
218-23
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:12021110-Adolescent,
pubmed-meshheading:12021110-Adult,
pubmed-meshheading:12021110-Aged,
pubmed-meshheading:12021110-Aged, 80 and over,
pubmed-meshheading:12021110-Aging,
pubmed-meshheading:12021110-Autoantibodies,
pubmed-meshheading:12021110-Autoantigens,
pubmed-meshheading:12021110-Child,
pubmed-meshheading:12021110-Diabetes Mellitus, Type 1,
pubmed-meshheading:12021110-High Mobility Group Proteins,
pubmed-meshheading:12021110-Humans,
pubmed-meshheading:12021110-Middle Aged,
pubmed-meshheading:12021110-SOXD Transcription Factors,
pubmed-meshheading:12021110-Sweden
|
pubmed:year |
2002
|
pubmed:articleTitle |
Increased autoantibodies to SOX13 in Swedish patients with type 1 diabetes.
|
pubmed:affiliation |
Department of Medicine, University of Lund, Lund, Sweden. Carina.Torn@med.lu.se
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|